

1 **A distinct metabolic profile associated with a fatal outcome in COVID-19 patients during early**  
2 **epidemic in Italy**

3

4 Elisa Saccon<sup>1</sup>, Alessandra Bandera<sup>2,3,4</sup>, Mariarita Sciumè<sup>5</sup>, Flora Mikeloff<sup>1</sup>, Abid Ali Lashari<sup>6</sup>, Stefano  
5 Aliberti<sup>3,7</sup>, Michael Sachs<sup>6</sup>, Filippo Billi<sup>8</sup>, Francesco Blasi<sup>3,7</sup>, Erin Gabriel<sup>6</sup>, Giorgio Costantino<sup>9,10</sup>,  
6 Pasquale De Roberto<sup>5</sup>, Shuba Krishnan<sup>1</sup>, Andrea Gori<sup>2,3,4</sup>, Flora Peyvandi<sup>3,11</sup>, Luigia Scudeller<sup>12</sup>,  
7 Christian L. Lorson<sup>13,14</sup>, Luca Valenti<sup>3,15</sup>, Kamal Singh<sup>13,14</sup>, Luca Baldini<sup>5,16</sup>, Nicola Stefano  
8 Fracchiolla<sup>5\*</sup> on behalf of the “COVID-19 NETWORK” working group<sup>#</sup>, Ujjwal Neogi<sup>1,13\*</sup>

9

10 <sup>1</sup>Division of Clinical Microbiology, Department of Laboratory Medicine, Karolinska Institute,  
11 Stockholm, Sweden

12 <sup>2</sup>Infectious Diseases Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

13 <sup>3</sup>Department of Pathophysiology and Transplantation, University of Milan, Milan, Italy

14 <sup>4</sup>Centre for Multidisciplinary Research in Health Science (MACH), University of Milan, Milan, Italy

15 <sup>5</sup>Hematology Unit, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

16 <sup>6</sup>Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden

17 <sup>7</sup>Internal Medicine Department, Respiratory Unit and Cystic Fibrosis Adult Center, Fondazione  
18 IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

19 <sup>8</sup>Acute Medical Unit, Department of Medicine, Fondazione IRCCS Ca' Granda Ospedale Maggiore  
20 Policlinico, Milan, Italy

21 <sup>9</sup>Department of Anesthesia, Critical Care and Emergency, Fondazione IRCCS Ca' Granda Ospedale  
22 Maggiore Policlinico, Milan, Italy

23 <sup>10</sup>Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy.

24 <sup>11</sup>Angelo Bianchi Bonomi Hemophilia and Thrombosis Center, IRCCS Ca' Granda Ospedale  
25 Maggiore Policlinico, Milan, Italy

26 <sup>12</sup>Clinical Trials Team, Scientific Direction, Fondazione IRCCS Ca' Granda Ospedale Maggiore  
27 Policlinico, Milan, Italy

28 <sup>13</sup>Bond Life Sciences Center, University of Missouri, Columbia, USA

29 <sup>14</sup>Department of Veterinary Pathobiology, University of Missouri, Columbia, USA

30 <sup>15</sup>Precision Medicine Unit, Department of Transfusion Medicine and Hematology, Fondazione IRCCS

31 Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

32 <sup>16</sup>Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy

33

34 \* Equal contribution

35 # All the names are reported in the acknowledgments section

36

37 **Keywords:** COVID-19, metabolomics, fatal outcome, Italy, predictive biomarkers

38

39 Corresponding authors:

40 Nicola Fracchiolla ([nicola.fracchiolla@policlinico.mi.it](mailto:nicola.fracchiolla@policlinico.mi.it)) and Ujjwal Neogi ([ujjwal.neogi@ki.se](mailto:ujjwal.neogi@ki.se))

41

42 **Abstract**

43 Leveraging the unique biological resource based upon the initial COVID-19 patients in Policlinico di  
44 Milano (Italy), our study provides the first metabolic profile associated with a fatal outcome. The  
45 identification of potential predictive biomarkers offers a vital opportunity to employ metabolomics in  
46 a clinical setting as diagnostic tool of disease prognosis upon hospital admission.

47

48 **Introduction**

49 As of February 2021, more than 100 million cases of coronavirus disease 2019 (COVID-19), caused  
50 by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, had been  
51 confirmed globally, with more than 2 million related deaths (<https://covid19.who.int/>). Although most  
52 individuals remain asymptomatic or display mild symptoms, 15-20% of patients exhibit severe  
53 symptoms, specifically respiratory distress, often requiring mechanical ventilation or/and intensive  
54 care (ICU) admission [1], with a mortality rate after ICU admission estimated around 40% [2].

55 Multiple studies have identified profound underlying conditions that demonstrate increased  
56 susceptibility to a more severe prognosis and a higher risk of fatality, including the male gender, old  
57 age [3], or certain underlying medical conditions, such as hypertension, cardiovascular diseases,  
58 diabetes or obesity [4]. Additionally, patients infected with SARS-CoV-2 present metabolic  
59 dysregulation, possibly due to immune-triggered inflammation or other changes in the host  
60 physiology, and that these alterations often reflect the disease severity [1,5,6]. For instance, levels of  
61 particular amino acids positively correlated with severe COVID-19 cases [1,7]. Moreover,  
62 perturbations in energy metabolisms, TCA and urea cycle [6] and lipid metabolism [1,8] are correlated  
63 to disease prognosis. Thus, it is essential to assemble a complete metabolic signature correlated to  
64 disease severity to identify a set of biomarkers strongly associated with the patient outcome, with the  
65 final goal of employing them for diagnostics and therapeutic purposes.

66 Our study retrospectively analyzes the metabolome profile of 75 COVID-19 patients with moderate  
67 and severe symptoms admitted to Policlinico di Milano (Lombardy region, Italy) following SARS-  
68 CoV-2 infection between March and April 2020. Italy was the first Western country to experience  
69 COVID-19 disease, and the Lombardy region was the epicenter of the Italian COVID-19 pandemic.

70 This cohort shows a higher mortality rate compared to others; therefore, it represents a unique  
71 opportunity to investigate the underlying metabolic profiles of the first COVID-19 patients in Italy and  
72 to identify potential predictive biomarkers.

73

#### 74 **Methods**

75 Plasma samples from 75 COVID19 patients were collected at the moment of admission to Policlinico  
76 di Milano (Italy) from March to April 2020 and SARS-CoV-2 positivity was confirmed by PCR  
77 (Ethical Clearance No. 462-2020-bis). Patients were initially classified based on the type of ventilation  
78 received: Nasal cannula (n=25) and VentMask (n=25) (moderate cases) or CPAP (n=25) (severe  
79 cases).

80 Plasma untargeted metabolomics was performed by Global Metabolomics (HD4) in Metabolon,  
81 (USA) as previously described [9]. The metabolomics method is ISO 9001:2015 certified and the lab  
82 is accredited by the College of American Pathologist (CAP), USA. Clinical data was collected from  
83 the registries.

84 Logistic regression was used to model associations of each biomarker with COVID-19-related in-  
85 hospital mortality adjusting for age, gender, and body mass index (BMI). As BMI was missing for  
86 many patients, multivariate imputation by chained equations (MICE) was used (via the MICE R-  
87 package) to impute BMI. Imputation was done in two stages, first including no biomarkers, and then  
88 including those biomarkers that were found to be significant under the original imputation. The  
89 resulting pooled estimates and inference were obtained using Rubin's rules. P-values were not adjusted  
90 in this analysis.

91 Metabolomics data were log<sub>2</sub> transformed and plotted using histograms with normal distribution  
92 superimposed. R package LIMMA was applied for differential abundance analysis between different  
93 mask types (Nasal cannula/VentMask/CPAP), outcome (survivors/non-survivors), and severity  
94 (moderate/severe). Adjustment for multiple testing was assessed using false discovery rate (FDR)  
95 <0.05. Heatmap was built using the R package ComplexHeatmap. Uniform Manifold Approximation  
96 and Projection (UMAP) representations were done using the R package UMAP. Metabolites with  
97 variance equal to zero were removed and positive significant pairwise correlations after Bonferonni

98 correction (Spearman, adjusted  $p < 0.00001$ ) were used for association analysis. The strength of the  
99 connections was evaluated by plotting distribution of correlation coefficients in a graphical network  
100 using igraph (<https://igraph.org/python/>). The network was compared to a random network with  
101 similar dimensions to validate the structure of the network to be not due to chance. Community  
102 detection was performed using Leiden algorithm  
103 (<https://leidenalg.readthedocs.io/en/stable/index.html>). For each community large enough ( $n > 30$ ),  
104 metabolite set enrichment analysis (MSEA) with KEGG and Metabolon terms via the Python module  
105 gseapy was performed. The average degree and clustering coefficient were calculated for each  
106 community. The final network was build using Cytoscape and biomarkers that were significantly  
107 associated with death were highlighted.

108

## 109 **Results and discussion**

110 Among the 75 patients enrolled in this study, 24% (18/75) succumbed to death in the hospital  
111 (Supplementary Table 1) and a significantly higher rate of fatal outcomes was observed for severe  
112 cases compared to moderate cases ( $p = 0.0218$ , Chi-square test). Among patients who died,  
113 comorbidities were nearly universally observed (94%, 17/18). Underlying conditions, like  
114 hypertension, were recorded for 46% (26/57) of the survivors and 50% (9/18) of the non-survivors,  
115 while cardiovascular diseases were significantly more common in non-survivors ( $p = 0.0320$ , Fisher's  
116 exact test) compared to survivors. Among the serological markers, lactate was significantly higher  
117 ( $p < 0.0001$ , Mann-Whitney test) in non-survivors compared to survivors, confirming its tight link to  
118 disease severity [10].

119 In a logistic regression analysis (adjusted to age, gender, and BMI), 35 metabolites, among the >1000  
120 tested, were significantly associated with COVID-19 mortality ( $p < 0.05$ , unadjusted), among which 10  
121 biomarkers were significant at the unadjusted 0.025 level (Figure 1A). Interestingly, cyclic adenosine  
122 monophosphate (cAMP) is significantly increased in non-survivors compared to survivors (OR: 7.4  
123 95% CI 1.5 - 37). cAMP is a well-known intracellular messenger that functions as a regulator of  
124 various cellular activities, including cell growth and differentiation, gene transcription, protein  
125 expression, and is intimately involved in mitochondrial dynamics [11]. As cAMP plays a role in

126 SARS-CoV-2 endocytosis in the initial phases of the infection [12], its involvement in disease  
127 progression is worthy of further investigations as a potential biomarker.

128 Using UMAP, we observed that the distribution of the patients in the biomarker enrichment showed a  
129 separation between survivors and non-survivors (Figure 1B). No specific pattern or clustering was  
130 observed for comorbidities (Fig 1C), the number of comorbidities (Fig 1D), or diabetes (Fig 1E),  
131 indicating that these metabolite sets only differentiate related to the clinical outcome.

132 To further understand the patterns of metabolic changes related to COVID-19, we performed a  
133 weighted correlation network analysis on the metabolomics dataset, using significant positive  
134 correlations (Spearman, adjusted  $p < 0.00001$ ). We identified 10 metabolites communities highly  
135 connected in a network of 916 nodes (metabolites) and 11453 edges (Figure 1F). Six predicted  
136 biomarkers (out of the 10 previously identified with  $p < 0.025$ , unadjusted) were highly correlated and  
137 were present in the network and belong to the lipid pathways. These metabolites are also known to be  
138 associated with peroxisomal fatty acid oxidation disorders (3-hydroxysebacate) [13] or insuline  
139 resistance (5-dodecenate (12:1n7), tetradecadienoate (14:2)\* and myristoleate (14:1n5)) [14].

140 Finally, to further discriminate the subset of metabolites significantly associated with a fatal clinical  
141 outcome, we selected all the biomarkers and their first neighbors in the network analysis previously  
142 described (238 metabolites). Based on these data, we found a clear clustering of non-survivors in  
143 opposition to survivors (Fig 1G). No clustering according to mask type was observed, indicating that  
144 the metabolic signature associated with mortality appears to be independent of the oxygen demand at  
145 the moment of hospitalization, providing the first identified correlation between a metabolite profile  
146 and disease severity in COVID-19 patients.

147 It is important to consider that when this study was planned (March-April 2020), there was little  
148 knowledge about the COVID-19. Therefore, several clinical data were missing. Despite that, this is the  
149 first set of biomarkers identified from high throughput metabolomics data that are associated with  
150 mortality and are not confounded by other preexisting conditions.

151

152 **Conclusions**

153 Our analysis has identified metabolic biomarkers that in our data differentiate between COVID-19  
154 survivors and non-survivors and that may be predictive of death from COVID-19, from the early stage  
155 of the epidemic, independently from oxygen demand at the moment of diagnosis. Our results on high  
156 throughput metabolomics contribute to a better understanding of COVID-19-related metabolic  
157 disruption and may represent a useful starting point for the identification of independent prognostic  
158 factors to be employed in the therapeutic practice.

159

#### 160 **Authors' contribution**

161 U.N. and N.S.F. designed the study. E.S., A.B., M.Sciumè, F.M., A.A.L., S.A., M.Sachs, F.Billi,  
162 F.Biasi, E.G., G.C., P.D., S.K., A.G., F.P., L.S. analyzed the data and performed the statistical  
163 analyses. E.S., U.N., N.S.F. wrote the paper. U.N. and K.S. acquired the fundings. E.S, C.L., L.V.,  
164 K.S., L.B., N.S.F., U.N. reviewed and edited the paper. All authors read and approved the final  
165 manuscript.

166

#### 167 **Funding**

168 The study was supported by Swedish Research Council Grants (2017-01330) and Karolinska Institute  
169 Stiftelser och Fonder (2020-01554) to U.N and by Office of Research, University of Missouri,  
170 Columbia, USA to K.S. E.S. was partially supported by VR (2020-05836).

171

#### 172 **Declaration of competing interest**

173 C.L.L is co-founder and CSO of Shift Pharmaceuticals. All other authors declare no competing  
174 conflicts of interest.

175

#### 176 **Acknowledgments**

177 The authors would also like to thank all patients involved in this study, as well as the dedicated  
178 medical and research staff who fight against SARS-CoV-2. We also like to acknowledge the work of  
179 the “COVID-19 NETWORK” working group:

180 Responsible person: Prof. Silvano Bosari

181 Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy

182 Scientific Direction: Silvano Bosari, Luigia Scudeller, Giuliana Fusetti, Laura Rusconi, Silvia

183 Dell'Orto. Transfusion Medicine (Biobank): Daniele Prati, Luca Valenti, Silvia Giovannelli.

184 Infectious Diseases Unit: Andrea Gori, Alessandra Bandera, Antonio Muscatello, Davide Mangioni,

185 Laura Alagna, Giorgio Bozzi, Andrea Lombardi, Riccardo Ungaro, Teresa Itri, Valentina Ferroni,

186 Valeria Pastore, Roberta Massafra, Iliaria Rondolini, Angelo Bianchi Bonomi. Internal Medicine,

187 Hemophilia and Thrombosis Center and Fondazione Luigi Villa: Flora Peyvandi, Roberta Gualtierotti,

188 Barbara Ferrari, Raffaella Rossio, Elisabetta Corona, Nicolò Rampi, Costanza Massimo. Internal

189 Medicine, Immunology and Allergology: Nicola Montano, Barbara Vigone, Chiara Bellocchi, Giulia

190 Coti, Mimma Sternativo. Respiratory Unit and Cystic Fibrosis Adult Center: Francesco Blasi, Stefano

191 Aliberti, Maura Spotti, Edoardo Simonetta, Leonardo Terranova, Francesco Amati, Carmen Miele,

192 Annalisa Vigni. Emergency Medicine: Giorgio Costantino, Monica Solbiati, Ludovico Furlan, Marta

193 Mancarella, Giulia Colombo, Giorgio Colombo. Acute Internal Medicine: Valter Monzani, Angelo

194 Rovellini, Filippo Billi, Christian Folli Internal Medicine: Marina Baldini, Irena Motta. General

195 Medicine and Metabolic Diseases: Anna Fracanzani, Rosa Lombardi. Geriatric Unit: Matteo Cesari,

196 Marco Proietti. Istituto di Ricerche Farmacologiche Mario Negri IRCCS: Alessandro Nobili, Mauro

197 Tettamanti.



198 **References**

- 199 [1] Shen B, Yi X, Sun Y, Bi X, Du J, Zhang C, et al. Proteomic and Metabolomic Characterization  
200 of COVID-19 Patient Sera. *Cell* 2020;182:59-72.e15.  
201 <https://doi.org/10.1016/j.cell.2020.05.032>.
- 202 [2] Armstrong RA, Kane AD, Cook TM. Outcomes from intensive care in patients with COVID-  
203 19: a systematic review and meta-analysis of observational studies. *Anaesthesia* 2020;75:1340–  
204 9. <https://doi.org/https://doi.org/10.1111/anae.15201>.
- 205 [3] Williamson EJ, Walker AJ, Bhaskaran K, Bacon S, Bates C, Morton CE, et al. Factors  
206 associated with COVID-19-related death using OpenSAFELY. *Nature* 2020;584:430–6.  
207 <https://doi.org/10.1038/s41586-020-2521-4>.
- 208 [4] Zhou Y, Yang Q, Chi J, Dong B, Lv W, Shen L, et al. Comorbidities and the risk of severe or  
209 fatal outcomes associated with coronavirus disease 2019: A systematic review and meta-  
210 analysis. *Int J Infect Dis* 2020;99:47–56. <https://doi.org/10.1016/j.ijid.2020.07.029>.
- 211 [5] Fraser DD, Slessarev M, Martin CM, Daley M, Patel MA, Miller MR, et al. Metabolomics  
212 Profiling of Critically Ill Coronavirus Disease 2019 Patients: Identification of Diagnostic and  
213 Prognostic Biomarkers. *Crit Care Explor* 2020;2:e0272–e0272.  
214 <https://doi.org/10.1097/CCE.0000000000000272>.
- 215 [6] Wu D, Shu T, Yang X, Song J-X, Zhang M, Yao C, et al. Plasma metabolomic and lipidomic  
216 alterations associated with COVID-19. *Natl Sci Rev* 2020;7:1157–68.  
217 <https://doi.org/10.1093/nsr/nwaa086>.
- 218 [7] Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, et al. Multi-Omics Resolves a Sharp  
219 Disease-State Shift between Mild and Moderate COVID-19. *Cell* 2020;183:1479-1495.e20.  
220 <https://doi.org/10.1016/j.cell.2020.10.037>.
- 221 [8] Song J-W, Lam SM, Fan X, Cao W-J, Wang S-Y, Tian H, et al. Omics-Driven Systems  
222 Interrogation of Metabolic Dysregulation in COVID-19 Pathogenesis. *Cell Metab*  
223 2020;32:188-202.e5. <https://doi.org/10.1016/j.cmet.2020.06.016>.
- 224 [9] Sperk M, Mikaeloff F, Svensson-Akusjärvi S, Ponnann SM, Nowak P, Sönnnerborg A, et al.  
225 Distinct Lipid Profile, Low-Level Inflammation and Increased Antioxidant Defense as a

- 226 Signature in HIV-1 Elite Control Status. SSRN Electron J 2020.  
227 <https://doi.org/10.2139/ssrn.3680819>.
- 228 [10] Li X, Xu S, Yu M, Wang K, Tao Y, Zhou Y, et al. Risk factors for severity and mortality in  
229 adult COVID-19 inpatients in Wuhan. *J Allergy Clin Immunol* 2020;146:110–8.  
230 <https://doi.org/10.1016/j.jaci.2020.04.006>.
- 231 [11] Di Benedetto G, Gerbino A, Lefkimmatis K. Shaping mitochondrial dynamics: The role of  
232 cAMP signalling. *Biochem Biophys Res Commun* 2018;500:65–74.  
233 <https://doi.org/https://doi.org/10.1016/j.bbrc.2017.05.041>.
- 234 [12] Aslam M, Ladilov Y. Targeting the sAC-Dependent cAMP Pool to Prevent SARS-Cov-2  
235 Infection. *Cells* 2020;9:1962. <https://doi.org/10.3390/cells9091962>.
- 236 [13] Muth A, Mosandl A, Wanders RJA, Nowaczyk MJM, Baric I, Böhles H, et al. Stereoselective  
237 analysis of 2-hydroxysebacic acid in urine of patients with Zellweger syndrome and of  
238 premature infants fed with medium-chain triglycerides. *J Inher Metab Dis* 2003;26:583–92.  
239 <https://doi.org/https://doi.org/10.1023/A:1025908216639>.
- 240 [14] Diboun I, Al-Mansoori L, Al-Jaber H, Albagha O, Elrayess MA. Metabolomics of  
241 Lean/Overweight Insulin-Resistant Females Reveals Alterations in Steroids and Fatty Acids. *J*  
242 *Clin Endocrinol Metab* 2021;106:e638–49. <https://doi.org/10.1210/clinem/dgaa732>.
- 243  
244  
245

246 **Table 1: Characteristics of the study population**

	Survivors	Non-survivors	<i>p value</i>
<i>Number</i>	57	18	
<i>Gender</i>			0.1169
- <i>Male (%)</i>	17 (30.4%)	9 (50%)	
- <i>Female (%)</i>	40 (69.4%)	9 (50%)	
<i>Age in years, median (IQR)</i>	62 (52-73.5)	76.5 (68.5-82)	0.0013
<i>BMI, median (IQR)*</i>	26.3 (24.4-29.5)	29.6 (27-32.2)	0.1697
<i>SpO2, median (IQR)*</i>	97 (94.25-98)	95 (89.25-98)	0.0768
<i>pH, median (IQR)*</i>	7.48 (7.45-7.5)	7.49 (7.45-7.53)	0.6672
<i>Lactate, median (IQR)*</i>	0.9 (0.7-1.1)	1.5 (1.1-1.8)	<0.0001
<i>Comorbidities (%):</i>	38 (66.7%)	17 (94%)	0.0297
- <i>Hypertension</i>	26 (46.4%)	9 (50%)	0.7913
- <i>Diabetes</i>	9 (16%)	3 (16.7%)	NS
- <i>Lung disease</i>	4 (7.1%)	1 (5.6%)	NS
- <i>COPD</i>	4 (7.1%)	2 (11.1%)	0.6257
- <i>Obesity</i>	8 (14.3%)	6 (33%)	0.0867
- <i>Renal disease</i>	4 (7.1%)	3 (16.7%)	0.3481
- <i>Liver disease</i>	1 (1.8%)	1 (5.6%)	0.4249
- <i>Cardiovascular disease</i>	7 (12.5%)	7 (38.9%)	0.0320
- <i>Cerebrovascular disease</i>	2 (3.6%)	0	NS
- <i>Others**</i>	14 (24.6%)	11 (61.1%)	
<i>Number of comorbidities (listed above):</i>			0.0047
- <i>None</i>	19 (33.4%)	1 (5.6%)	
- <i>One</i>	16 (28%)	3 (16.7%)	
- <i>Two</i>	9 (15.8%)	6 (33%)	
- <i>Three or more</i>	13 (22.8%)	8 (44.4%)	
<i>Disease severity§:</i>			0.0218
- <i>Moderate</i>	42 (73.7%)	8 (44.4%)	
- <i>Severe</i>	15 (26.3%)	10 (55.6%)	

\* Calculated from the available data

\*\* Gastrointestinal reflux, dyslipidemia, neoplasia, dementia

§ Based on the masks

248 **Figure legends:**

249 **Figure 1: 10 metabolites are significantly associated with COVID-19 related in-hospital**

250 **mortality.**

251 A. All biomarkers that were significant at the 0.05 level, after adjustment of age, gender, and BMI,  
252 were included in the plot and order by the value of the odds ratio. Color coding for lower p-values is  
253 presented in the legend.

254 B-E. UMAP visualization of patients' data after selecting the 10 death biomarkers. Patients were  
255 labeled for the B. outcome, C. presence of comorbidities, D. amount of comorbidities and E. diabetes.

256 F. Global weighted network after communities' detection. Biomarkers with COVID-19 related  
257 mortality belong to communities 4 and 5 (labeled). The size of the bubble represents the connectivity  
258 of each metabolite.


259 G. Heatmap of potential biomarkers and first neighbors in patients. Outcome (survivors/non-survivors)  
260 and mask type is indicated. Data were log-transformed.

261


262

A.


medRxiv preprint doi: <https://doi.org/10.1101/2021.04.13.21255117>; this version posted April 15, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).




B. Reprint




C.




D.



E.



F.



G.

